It is an open-label, 3+3 design dose escalation study involving three dosages (of 2×10^11vg/kg，6×10^11vg/kg，and 2×10^12vg/kg) aimed to explore the safety, pharmacokinetics, immunology and preliminary efficacy of JV001.
The aim of this study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing a modified telomerase protein (TERT), driven by cardiac troponin T promoter (AAV9-cTnT-modTERT), to 15 dilated cardiomyopathic patients.